Navigation
banner

Antibody & Protein Therapeutics Summit

2018-04-192018-09-112018-07-24
EARLY BIRD DISCOUNT! Register by Jul 24, 2018 to receive 20% off your registration!
Or Register 3 for the price of 2 with the coupon code rcdvb!


The 2018 full agenda is currently in process.

Please come back and visit this page for updates.

BELOW IS THE FULL AGENDA FROM 2017.

ssclaas=mixsessionprlval=1Array ( [328] => 1 )
Day 1 - Tuesday, July 11, 2017
7:00
Continental Breakfast & Registration
ssclaas=mixsessionprlval=1Array ( [328] => 1 )
8:15
Opening Remarks by GTCbio
ssclaas=mixsessionprlval=1Array ( [328] => 1 )
ssclaas=mixsessionprlval=1Array ( [328] => 1 )
ssclaas=mixsessionprlval=1Array ( [328] => 1 )
10:00
Into the Deep: High-Throughput Screening of Natural Immune B Cell Repertoires to Discover Rare Antibodies with Defined Properties
 
Veronique Lecault
Veronique Lecault
Co-Founder
AbCellera
About Speaker: Dr. Lecault is co-founder of AbCellera, a Canadian biotechnology company focused on the discovery of therapeutic antibodies from natural immune repertoires. She received her PhD in Chemical and Biological Engineering from the University of British Co... Read Full Bio 
 
 
Veronique Lecault
Veronique Lecault
Co-Founder
AbCellera
 
About Speaker:

Dr. Lecault is co-founder of AbCellera, a Canadian biotechnology company focused on the discovery of therapeutic antibodies from natural immune repertoires. She received her PhD in Chemical and Biological Engineering from the University of British Columbia, where she trained under the supervision of Dr. James Piret and Dr. Carl Hansen. During her studies she developed a microfluidic mammalian cell culture platform that allowed for monitoring of thousands of single hematopoietic stem cells at once, and for clonal selection of high-secreting cell lines for antibody production. Prior to this, she simultaneously obtained a B.Sc. in Biochemistry/Biotechnology and a B.A.Sc. in Chemical Engineering, summa cum laude, from the University of Ottawa.

 
Abstract: Immune systems from humans and other ...Read More 

Immune systems from humans and other jawed vertebrates have naturally evolved to produce highly specific antibodies to fight diseases and infections. The majority of approved therapeutic antibodies have been generated from natural immune sources using hybridoma or display technologies, however finding antibodies with functional properties against increasingly challenging targets requires more powerful screening tools. AbCellera has developed a rapid, high-throughput platform for the screening of natural immune repertoires, enabling the simultaneous analysis of millions of single antibody-secreting cells for the rapid identification of monoclonal antibodies from any species. The combination of throughput with a wide array of single-cell screening assays such as multiplexed binding, species cross-reactivity, ligand blocking, and various cell-based assays allows for the identification of antibodies with desired properties and greater diversity while accelerating the advancement of therapeutic programs. This presentation will highlight recent examples in which high-throughput single B cell screening has been successfully applied to the discovery of antibodies against infectious diseases and immuno-oncology targets.

 Read Less
ssclaas=mixsessionprlval=1Array ( [328] => 1 )
10:25
CSPG4, an Attractive Target of Antibody-Based Immunotherapy for the Treatment of Solid Tumors
 
Soldano Ferrone
Soldano Ferrone
Professor, Department of Surgery
MGH/Harvard Medical School
About Speaker: Soldano Ferrone received his MD and PhD degrees in 1964 and in 1971, respectively, from the University of Milan, Milan, Italy. He has held faculty positions at the University of Milan, Milan, Italy, Scripps Clinic and Research Foundation, La Jolla, C... Read Full Bio 
 
 
Soldano Ferrone
Soldano Ferrone
Professor, Department of Surgery
MGH/Harvard Medical School
 
About Speaker:

Soldano Ferrone received his MD and PhD degrees in 1964 and in 1971, respectively, from the University of Milan, Milan, Italy. He has held faculty positions at the University of Milan, Milan, Italy, Scripps Clinic and Research Foundation, La Jolla, CA, Columbia University, New York, NY, New York Medical College, Valhalla, NY, Roswell Park Cancer Institute, Buffalo, NY and at the University of Pittsburgh School of Medicine, Pittsburgh, PA. Since 2012 he is a faculty member of the Department of Surgery at Massachusetts General Hospital, Harvard Medical School, Boston, MA. Dr. Ferrone has received many awards and honors. For the last 30 years he has been the member of many review committees including NIH Study Sections, and of the editorial boards of many scientific journals. Furthermore he is the member of several external scientific boards. Dr. Ferrone’s research program focuses on the molecular characterization of escape mechanism(s) utilized by tumor cells to avoid immune recognition and destruction and on the development of combinatorial immunotherapeutic strategies to counteract the escape mechanism(s) utilized by tumor cells. These studies are greatly facilitated by the large panel of HLA antigen- and human tumor antigen-specific monoclonal antibodies he has developed and shared with the scientific community over the years. He has described the results of his studies in more than 600 papers published in peer reviewed journals. Moreover he has been the editor of 14 books and the guest editor of 5 special issues of oncology journals.

 
Abstract: The high frequency of defects in HLA ...Read More 

The high frequency of defects in HLA class I antigen presentation machinery which have been found in all the solid tumors analyzed suggests that abnormalities in the ability of tumor cells to present tumor antigen derived peptides to cognate T cells may represent a major obstacle to the successful application of T cell-based immunotherapy for the treatment of solid malignancies. This finding provides a strong rationale for the use of antibody-based immunotherapy. In this light we will describe the characteristics of the tumor antigen CSPG4 and discuss why we believe that this tumor antigen is an attractive target for the treatment of various types of solid tumors.

 Read Less
ssclaas=mixsessionprlval=1Array ( [328] => 1 )
10:50
Morning Networking Break
ssclaas=parallelprlval=1Array ( [330] => 1 [329] => 1 [328] => 1 )
Antibodies in Oncology & Beyond 2017
Strategies for Antibodies Against Infectious Diseases
Moderator: Janos Luka, Walter Reed Army Institute of Research
11:20
Identifying Diagnostic and Therapeutic Targets of Drug Resistant Microbes Through in vivo Proteomic Analysis
 
Janos Luka
Janos Luka
Ph.D. Scientist, Bacterial Diseases
Walter Reed Army Institute of Research
About Speaker: Janos Luka received his Ph.D. in Tumor virology and Immunology at Karolinska Institutet in Stockholm, Sweden, where his research was concentrated on Epstein - Barr virus and its role in B-cell lymphomas. He completed a postdoctoral fellowship at Mayo... Read Full Bio 
 
 
Janos Luka
Janos Luka
Ph.D. Scientist, Bacterial Diseases
Walter Reed Army Institute of Research
 
About Speaker:

Janos Luka received his Ph.D. in Tumor virology and Immunology at Karolinska Institutet in Stockholm, Sweden, where his research was concentrated on Epstein - Barr virus and its role in B-cell lymphomas. He completed a postdoctoral fellowship at Mayo Clinic Rochester, Minnesota, where he developed the first commercialized ELISA test for detection of EBV associated diseases. He moved to Georgetown University and worked on lymphotropic herpesviruses and developed several diagnostic assays for detection of lymphotropic herpes viruses. As Associate Professor at At Eastern Virginia Medical school he established a CAP accredited diagnostic laboratory focused on viral infections, which he directed for nine years. In 2003 he established a biotechnology company and was associated with several biotechnology companies to characterize and produce monoclonal antibodies for clinical trials. He has co-authored over 100 peer-reviewed papers and has extensive management, and business experience. At present his research work is focused on diagnostic assay development for bacterial and fungal infections and developed a unique method to produce fully human therapeutic monoclonal antibodies against drug resistant infectious diseases.

 
Abstract: Bacterial diseases are a major cause ...Read More 

Bacterial diseases are a major cause of death throughout the world as a result of the emergence of new infectious agents, increased transmission due to human migration, and the development of antibiotic resistance. Novel therapies are needed to control these infections, together with new rapid and reliable diagnostic techniques for characterizing resistant strains. The most vital step in development of diagnostic assays and therapeutic antibodies is to identify the key antigens and epitopes targeted by immune responses. To achieve this, we applied an In Vivo Antigen Discovery (IVAD) technique to identify bacterial proteins expressed in vivo during infection with Acinetobacter baumannii, a gram-negative bacterium frequently associated with traumatic and hospital acquired infections. A mouse hybridoma library was developed by immunizing naïve mice with serum from A. baumannii infected mice. The pool of monoclonal antibodies present in the library was used to identify antigens in serum from infected animals, and serum from A. baumannii infected patients. More than one hundred hybridoma clones have been isolated and their target identified. These targets represent proteins with known or potential roles in the pathogenesis of A. baumannii. Several antibodies have been identified as candidates for clinical diagnosis of A. baumannii infections and are under development for use in diagnostic assays. Opsonization of A. baumannii was demonstrated with three of the antibodies, while two antibodies inhibited in vitro biofilm formation. These antibodies are under evaluation in vivo for their ability to prevent and/or treat Multi Drug Resistant A. baumannii infections and to inhibit biofilm formation. To develop therapeutic human antibodies, without the need of humanization of the mouse antibodies, human sera from previously infected patients were commercially purchased and screened for presence of antibodies against antigens where the corresponding mouse monoclonal antibodies were effective in functional assays. By examining convalescent-phase human serum samples we identified that most of these sera had antibodies to majority of the antigens identified by mouse antibodies. Using our rapid human antibody cloning method, fully human monoclonal antibodies are generated from memory B-cells of these individuals. These antibodies will be evaluated in vivo and in vitro for their ability to prevent and/or treat A. baumannii infections. The described in vivo proteomic approach has significant advantages over other due to the large collection of antigen specific hybridomas which can be quickly screened for diagnostic assay developments and therapeutics. Presently similar work is in progress to identify diagnostic and therapeutic targets for Staphylococcus aureus and Klebsiella pneumoniae infections.

 Read Less
Antibody Drug Conjugates 2017
Important Considerations During Preclinical Development
Moderator: Andrew Tsourkas, University of Pennsylvania
11:20
Characterization of ADME Properties of Novel Protein Therapeutics
 
Cinthia Pastuskovas
Cinthia Pastuskovas
Senior Scientist, Pharmacokinetics and Drug Metabolism
Amgen
About Speaker: Cinthia Pastuskovas received her PhD in Neurosciences at the University of Cordoba, Argentina and continued her line of research as a postdoctoral fellowship at the University of Iowa investigating the neuronal mechanisms activated under conditions o... Read Full Bio 
 
 
Cinthia Pastuskovas
Cinthia Pastuskovas
Senior Scientist, Pharmacokinetics and Drug Metabolism
Amgen
 
About Speaker:

Cinthia Pastuskovas received her PhD in Neurosciences at the University of Cordoba, Argentina and continued her line of research as a postdoctoral fellowship at the University of Iowa investigating the neuronal mechanisms activated under conditions of sodium depletion in pharmacological rat models of sodium depletion. In 2002 Cinthia was hired by Genentech, Inc to support target validation and therapeutic antibody selection by characterizing in vitro/in vivo kinetics of absorption, distribution, catabolism, and excretion of large molecules for various therapeutic areas.

 
Abstract: Next generation protein therapeutics ...Read More 

Next generation protein therapeutics are engineered in an attempt to improve the efficacy of monoclonal antibody therapeutics in the oncology setting. These multifunctional therapeutics are designed for enhanced pharmacologic activity or improved target selectivity. Altering the targeting and/or activity of a molecule can concomitantly lead to novel and unanticipated ADME properties and pharmacokinetics for the therapeutic. This presentation summarizes methods for the characterization of the stability and overall disposition of bispecific antibodies and antibody-cytokine fusion proteins to help guide engineering and selection of lead candidates.

 Read Less
Novel Protein Therapeutics 2017
Targeting Disease with Non-Antibody Scaffolds & Polyclonal Antibodies
Moderator: Srinath Kasturirangan, MedImmune
11:20
AlbuCORE: a Novel Scaffold Platform Based on Human Serum Albumin
 
Mario Sanches
Mario Sanches
Senior Scientist, Protein Engineering
Zymeworks
About Speaker: Mario Sanches is a Senior Scientist with the Protein Engineering department at Zymeworks. He has a B.S. degree and an M.S. in Chemistry, and a Ph.D. in Biomolecular Physics from the Sao Paulo University (Brazil). He has an extensive knowledge in stru... Read Full Bio 
 
 
Mario Sanches
Mario Sanches
Senior Scientist, Protein Engineering
Zymeworks
 
About Speaker:

Mario Sanches is a Senior Scientist with the Protein Engineering department at Zymeworks. He has a B.S. degree and an M.S. in Chemistry, and a Ph.D. in Biomolecular Physics from the Sao Paulo University (Brazil). He has an extensive knowledge in structural biology and macromolecular structural characterization and analysis, having held positions as Research Fellow at the Brazilian Synchrotron (Brazil), visiting Research Fellow at the National Cancer Institute at Frederic (USA), and a CCSRI Postdoctoral Research Fellow at the Samuel Lunenfeld Research Institute in Toronto (Canada). Over the past five years Mario has been involved in a number of rational scaffold engineering and drug development efforts, including Zymeworks' Azymetric and AlbuCORE platforms.

 
Abstract: Using rational in silico engineering ...Read More 

Using rational in silico engineering approaches we designed a family of quasi-native split Human Serum Albumin (HSA) molecules with novel engineered amino and carboxyl termini. These new termini enable the design of multi-valent and multi-functional fusion molecules. AlbuCORE retains HSA-like pharmacokinetics and biophysical properties and presents favorable features regarding manufacturability. We generated proof-of-concept multi-valent multi-specific fusion molecules using antibody Fab or scFv moieties fused to AlbuCORE. We also created a series of 1X to 4X fusions using all possible AlbuCORE termini. All fusions bind their targets, and higher valence leads to higher affinity, however, affinity and avidity are highly dependent on the binding-moiety orientation and geometry. Overall, splitting HSA to create AlbuCORE scaffolds preserved the HSA-like properties of these molecules.

 Read Less
ssclaas=parallelprlval=1Array ( [330] => 1 [329] => 1 [328] => 1 )
11:45
Generation of “Fully Human” Monoclonal Antibodies from Human-Immune-System Humanized DRAGA Mice
 
Sofia Casares
Sofia Casares
Director Pre-Clinical Research & Concept Development
Walter Reed Army Institute of Research
About Speaker: Dr. Sofia Casares is the Director of Pre-Clinical Research in the Division of Malaria at the Naval Medical Research Center/Walter Reed Army Institute of Research. She obtained her PhD in 1991 from the Universidad Autonoma de Madrid, received doctoral... Read Full Bio 
 
 
Sofia Casares
Sofia Casares
Director Pre-Clinical Research & Concept Development
Walter Reed Army Institute of Research
 
About Speaker:

Dr. Sofia Casares is the Director of Pre-Clinical Research in the Division of Malaria at the Naval Medical Research Center/Walter Reed Army Institute of Research. She obtained her PhD in 1991 from the Universidad Autonoma de Madrid, received doctoral trainings at California Institute of Biological Research and at Mount Sinai School of Medicine (MSSM) followed by a Faculty appointment in the Department of Microbiology, MSSM with research focused in the field of autoimmunity and immunotherapy. Her laboratory at the Naval Medical Research center/Walter Reed Army Institute of Research generated the humanized HLA-expressing DRAGA mouse model that sustains infection with Plasmodium falciparum malaria, HIV, dengue, and scrub typhus, and also elicit immune responses upon vaccination. The humanized mouse models are currently being used for generation of human therapeutic monoclonal antibodies against infectious diseases.

 
Abstract: Fully human monoclonal antibodies (mA...Read More 

Fully human monoclonal antibodies (mAb) are envisioned as new therapeutic approaches for neutralization of infectious agents/toxins, while devoid of side effects associated to the use of mouse, chimeric, or humanized mAbs. The current challenge for generation of fully human mAbs is the paucity of specific B cells in human blood, since antibody-secreting plasma cells reside in lymphoid organs and in the bone marrow. Approaches that use EBV-transformed human B cells pose challenges for further development into clinical use, since EBV is a relevant human pathogen. We have generated humanized mice expressing HLA class I and class II molecules in a NOD.RagKO.IL2RgcKO background (DRAGA mice). Upon infusion of HLA-matched human hematopoietic stem cells from umbilical cord blood, the DRAGA mice develop functional human B cells that secrete specific IgG antibodies upon vaccination. Using human B cells from immunized DRAGA mice we have generated human monoclonal antibodies against P. falciparum malaria, Ebola, and influenza. The DRAGA mouse model represents an easy, convenient, and rapid approach for generation of fully human therapeutic monoclonal antibodies against infectious diseases.

 Read Less
11:45
Radiolabeled Antibodies for Imaging EGFR by PET/SPECT
 
Humphrey Fonge
Humphrey Fonge
Assistant Professor of Medical Imaging
College of Medicine, University of Saskatchewan, Canada
About Speaker: Dr. Fonge is an assistant professor of medical imaging at the University of Saskatchewan (UofS) Canada and radiopharmacist at the Royal University Hospital (RUH) - Saskatoon. He is also the nominated head of preclinical molecular imaging program at U... Read Full Bio 
 
 
Humphrey Fonge
Humphrey Fonge
Assistant Professor of Medical Imaging
College of Medicine, University of Saskatchewan, Canada
 
About Speaker:

Dr. Fonge is an assistant professor of medical imaging at the University of Saskatchewan (UofS) Canada and radiopharmacist at the Royal University Hospital (RUH) - Saskatoon. He is also the nominated head of preclinical molecular imaging program at UofS and the co-director of the Center for Biologics Imaging Research and Development.

 
Abstract: Mutations that lead to epidermal grow...Read More 

Mutations that lead to epidermal growth factor receptor (EGFR) upregulation are associated with a number of cancers, including glioblastoma, anal cancers, squamous-cell carcinoma of the lung and epithelial tumors of the head and neck. EGFR has four binding domains that interact with its ligands or antibodies (domains I, II, III and IV). All approved therapeutic anti-EGFR antibodies such as cetuximab and panitumumab bind to domains I and III. Existing ex vivo assays for monitoring EGFR expression such as IHC, FISH and qPCR are invasive and not very reliable at predicting EGFR expression. These techniques require frequent biopsies that is not possible for most patients. Biopsy sampling is inherently flawed because of the intratumoral heterogeneity. In vivo imaging of EGFR expression offers several advantages over current ex vivo methods. These include assessment of EGFR expression of the entire tumor volume rather than just a portion of the tumor (thereby addressing the intrinsic heterogeneity of receptor expression), assessment of the biologic availability of EGFR in vivo, and evaluation the effects of anti-EGFR therapies. To this end, we have developed radiolabeled anti-EGFR antibodies for imaging the receptor by PET/SPECT. We have developed radiolabeled anti-EGFR antibodies that target domains I, II or III of the receptor which offer unique applications for imaging. This presentation will include recent preclinical data of these radiolabeled antibodies.

 Read Less
11:45
Targeting Cancer with Prosthetic Antigen Receptor T-cells
 
Jacob Petersburg
Jacob Petersburg
PhD Candidate - Wagner Laboratory Department of Medicinal Chemistry
University of Minnesota
About Speaker: Jacob received his B.A. from Saint John’s University in 2011 where he majored in Biochemistry. Following his graduation Jacob worked at Boston Scientific as a product performance analyst for one year prior to continuing his education at the Univers... Read Full Bio 
 
 
Jacob Petersburg
Jacob Petersburg
PhD Candidate - Wagner Laboratory Department of Medicinal Chemistry
University of Minnesota
 
About Speaker:

Jacob received his B.A. from Saint John’s University in 2011 where he majored in Biochemistry. Following his graduation Jacob worked at Boston Scientific as a product performance analyst for one year prior to continuing his education at the University of Minnesota. He is a Ph.D. Candidate in Medicinal Chemistry where he has trained under the supervision of Dr. Carston Wagner. Jacob’s research focused on the successful development of a novel protein based platform, Prosthetic Antigen Receptors (PARs), for anti-cancer immunotherapy and non-genetic engineering of cell surfaces.

 
Abstract: Our laboratory has developed prosthet...Read More 

Our laboratory has developed prosthetic antigen receptors (PARs) as a non-genetic system for enabling cells to bind multiple surface receptors simultaneously and have been successfully employed in vitro to redirect T cells for the selective cell killing of leukemia cells. However, PAR efficacy has yet to be evaluated against a solid tumor cancer model or In Vivo. To address these questions, we developed PARs selectively targeting the Epithelial Cell Adhesion Molecule (EpCAM) receptor overexpressed on multiple carcinoma and cancer stem cells. Our results demonstrated that PAR-functionalized CD3+ T-cells selectively recognize EpCAM+ MCF-7 breast cancer cells and undergo subsequent activation and cell killing only in the presence of target cells. Furthermore, an orthotopic breast cancer model validated the ability of PAR therapy to redirect T-cell activity towards EpCAM+ breast cancer cells in vivo. More specifically, PAR-functionalized CD3+ T-cells were shown to completely eradicate the EpCAM+ tumors in vivo without the need for daily dosing. Tissue specific targeting was also accompanied by T-cell differentiation into both central memory and effector memory cells in the presence of therapy. A unique benefit of PAR therapy is the capability to quickly deactivate and remove the PARs from T cells by incubation with the FDA-approved antibiotic trimethoprim, at clinically relevant concentrations, in order to stop further cellular activation. Taken together, our results demonstrate that PARs provide a promising platform for future use in cell-directed cancer immunotherapy.

 Read Less
ssclaas=parallelprlval=1Array ( [330] => 1 [329] => 1 [328] => 1 )
12:10
 
Jacob Glanville
Jacob Glanville
CSO
Distributed Bio Inc.
About Speaker: Jake grew up in a village in the highlands of Guatemala, but returned to the first world to solve problems in computational immunology. He went from the Tzutujile village of Santiago Atitlan in Guatemala to an undergraduate in Genetics, Genomics and ... Read Full Bio 
 
 
Jacob Glanville
Jacob Glanville
CSO
Distributed Bio Inc.
 
About Speaker:

Jake grew up in a village in the highlands of Guatemala, but returned to the first world to solve problems in computational immunology. He went from the Tzutujile village of Santiago Atitlan in Guatemala to an undergraduate in Genetics, Genomics and Development research at UC Berkeley, to become Principal Scientist at Pfizer, to entering into and in the process of completing a PhD in Computational and Systems Immunology at Stanford University School of Medicine, and now Chief Science Officer and Co-founder of Distributed Bio.

He is a field leader in antibody, TCR and pMHC repertoire algorithms and methods development, having published multiple early defining manuscripts and patents to combine next generation sequencing, protein engineering, immunology, and algorithm development to interrogate antibody repertoires and optimize their responses towards therapeutic applications. He personally developed the core algorithms that allowed Distributed Bio to become profitable within the first year of founding, with clients and collaborators now including 7 of the top 10 pharma, multiple research institutions, the Stanford Hospital Blood and Marrow transplant clinic and over 30 biotechnology and academic institutions internationally.

As a UC Berkeley undergraduate, Jacob Glanville performed research in two academic laboratories, Dr. Glenys Thomson's HLA Population Genetics laboratory, and Dr. Sjolander's Berkeley Phylogenomics Group, where in the latter, as an undergrad, he begin publishing first-author publications. In March 2008, Jacob was recruited to Pfizer's Rinat Antibody Therapeutics research facility, he developed novel computational immunology methods for characterizing and optimizing functions of the adaptive immune system, engineering molecules for drug development, and was promoted every year for four consecutive years to become Principal Scientist by 2012. In 2012 he left Pfizer with a vision to create Distributed Bio and bring routine antibody repertoire analytics to the masses.

In parallel with co-leading the now-profitable Distributed Bio, he is working to complete a PhD in Computational and Systems Immunology at Stanford University, coadvised by Mark Davis and Scott Boyd and in collaboration with multiple other laboratories including the Nadeau, Maecker, Martinez, Engleman, and Chien labs.

12:10
Development of Tubulysin Analogs for Antibody Drug Conjugates
 
Changshou Gao
Changshou Gao
Senior Director/Fellow, Department of Antibody Discovery & Protein Engineering
MedImmune
About Speaker: Changshou Gao Ph.D. is currently a Senior Director/Fellow in the Department of Antibody Discovery and Protein Engineering at MedImmune, a subsidiary of AstraZeneca. Dr. Gao has over 25 years’ experience in recombinant antibody generation (phage, ye... Read Full Bio 
 
 
Changshou Gao
Changshou Gao
Senior Director/Fellow, Department of Antibody Discovery & Protein Engineering
MedImmune
 
About Speaker:

Changshou Gao Ph.D. is currently a Senior Director/Fellow in the Department of Antibody Discovery and Protein Engineering at MedImmune, a subsidiary of AstraZeneca. Dr. Gao has over 25 years’ experience in recombinant antibody generation (phage, yeast, and mammalian display), antibody engineering, protein expression and antibody drug development and has published over 50 peer-reviewed papers and 30 patent applications. From 1994 to 2002, Dr. Gao received his Ph.D. from and also conducted his postdoc studies at The Scripps Research Institute focusing on catalytic antibodies and antibody discoveries using phage display. Dr. Gao then joined MedImmune in 2002 to establish the phage display capability for lead antibody identification. After a couple of year's effort on antibody lead generation, he is now leading a team responsible for antibody drug conjugates, bispecific antibodies, large scale antibody transient expression, gene therapy, and other new technology development for the next generation of biologics.

12:10
Cytosolic Delivery of Receptor-Targeted Binding Proteins
 
Wouter Verdurmen
Wouter Verdurmen
Research Associate, Department of Biochemistry
Radboud University Medical Centre
About Speaker: Dr. Verdurmen has done his PhD on the cellular delivery of biomacromolecules at the Radboud University in Nijmegen, the Netherlands, focusing on the use of cell-penetrating peptides. After finishing his PhD cum laude in 2012, he received a postdoctor... Read Full Bio 
 
 
Wouter Verdurmen
Wouter Verdurmen
Research Associate, Department of Biochemistry
Radboud University Medical Centre
 
About Speaker:

Dr. Verdurmen has done his PhD on the cellular delivery of biomacromolecules at the Radboud University in Nijmegen, the Netherlands, focusing on the use of cell-penetrating peptides. After finishing his PhD cum laude in 2012, he received a postdoctoral fellowship that he used to join the laboratory of Andreas Plückthun in order to work on developing a quantitative assay for measuring cytosolic delivery, which he then employed to investigate engineered modular protein transport systems. In 2016, he received an early career grant to start an independent line of research in Nijmegen, the Netherlands, where he is now further developing therapeutic protein delivery methods and assessing their potential in complex 3D models using microfluidic systems.

 
Abstract: Delivery of intact proteins to the cy...Read More 

Delivery of intact proteins to the cytosol of mammalian cells has huge therapeutic potential as novel targets could be addressed that have thus far been considered undruggable. In general, cells do not permit access of polar macromolecules such as proteins to their cytosol, but nature has evolved a number of approaches to deliver entire, functional proteins into the cytosol. Aiming to exploit efficient mechanisms utilized by bacterial toxins, an assay employing the prokaryotic enzyme biotin ligase for the accurate determination of cytosolic delivery was developed [1]. Subsequently, modular protein transport systems were constructed that consisted of a receptor-targeted binding protein, a bacterial toxin-derived endosomal escape moiety, and a binding protein that exerts an intracellular activity [2]. We show that cytosolic delivery can be achieved with these transporters, and that rational protein engineering strategies can be utilized for improving the toxicity, delivery and cytosolic stability of the uptake systems. A comparison of these systems with cell-penetrating peptides and supercharged proteins shows that only toxin-derived systems can combine cell-type specificity with an efficient cytosolic delivery.

[1] W.P. Verdurmen, M.Mazlami and A. Plückthun, Methods in Molecular Biology, 1575, 223-236 (2017)
[2] W.P. Verdurmen, M. Luginbühl, A. Honegger and A. Plückthun, Journal of controlled release, 200, 13-22 (2015)

Benefits:

  • Designed ankyrin repeat proteins as a promising non-antibody scaffold
  • Receptor-targeted delivery for cell-selective targeting
  • Exploitation of nature-inspired mechanisms to achieve cytosolic access
  • Targeting approach for previously undruggable intracellular targets
 Read Less
ssclaas=parallelprlval=1Array ( [329] => 1 [328] => 1 )
12:35
Lunch on Your Own
12:35
An Antidote Approach to Reduce Risk and Broaden Utility of Antibody Based Therapeutics
 
Alyse Portnoff
Alyse Portnoff
Post Doc, Department of Antibody Discovery and Protein Engineering
Medimmune
About Speaker: ... Read Full Bio 
 
 
Alyse Portnoff
Alyse Portnoff
Post Doc, Department of Antibody Discovery and Protein Engineering
Medimmune
 
About Speaker:
ssclaas=mixsessionprlval=1Array ( [328] => 1 )
12:50
Lunch on Your Own
ssclaas=parallelprlval=1Array ( [330] => 1 [329] => 1 [328] => 1 )
Antibodies in Oncology & Beyond 2017
Immunotherapeutic Approaches in Oncology
Moderator: John Ross, Cue Biopharma
1:45
ProTIA – Bispecific T Cell Engagers Designed for Activation by Tumor-Associated Proteases Based on XTEN® Protein Polymer
 
Fan Yang
Fan Yang
Associate Director, Research & Discovery
Amunix
About Speaker: Originally trained as a structural biologist at Pamela Bjorkman's lab at Caltech, Fan is now leading the discovery effort at Amunix on multiple partner and internal projects based on its proprietary XTEN technology, including the novel ProTIA platfor... Read Full Bio 
 
 
Fan Yang
Fan Yang
Associate Director, Research & Discovery
Amunix
 
About Speaker:

Originally trained as a structural biologist at Pamela Bjorkman's lab at Caltech, Fan is now leading the discovery effort at Amunix on multiple partner and internal projects based on its proprietary XTEN technology, including the novel ProTIA platform for oncology, which she will share with you today.

 
Abstract: Amunix developed an novel format of b...Read More 

Amunix developed an novel format of bispecific T cell engagers called ProTIA (Protease Triggered Immune Activators). ProTIA molecules utilize our proprietary XTEN™ protein polymer for half-life extension and to enable rapid microbial production as single polypeptide chain. XTENylated ProTIA molecules act as prodrugs with low systemic toxicity that can be selectively activated at the tumor site by tumor-associated proteases. This prodrug format expands the therapeutic window of ProTIA molecules relative to other bispecific formats. We will show comprehensive data for AMX-168 which is indicated for ovarian cancer with potential use in multiple additional solid malignancies.

 Read Less
Antibody Drug Conjugates 2017
Payloads, Linkers, and Alternative Strategies in ADCs
Moderator: Soldano Ferrone, MGH/Harvard Medical School
1:45
Improving the Activity of Chemotherapeutics Delivered by Antibody-Drug Conjugates with Integrated Endosome Escape and Nuclear-Directional Trafficking Control Capabilities
 
Victor-Jeffrey Leyton
Victor-Jeffrey Leyton
Assistant Professor, Department of Nuclear Medicine and Radiobiology
‎Université de Sherbrooke
About Speaker: Dr. Leyton trained under world-renowned researchers in the fields of antibody engineering and radioimmunoconjugates obtaining his Doctorate in 2008 from the University of California at Los Angeles followed by postdoctoral training at the University o... Read Full Bio 
 
 
Victor-Jeffrey Leyton
Victor-Jeffrey Leyton
Assistant Professor, Department of Nuclear Medicine and Radiobiology
‎Université de Sherbrooke
 
About Speaker:

Dr. Leyton trained under world-renowned researchers in the fields of antibody engineering and radioimmunoconjugates obtaining his Doctorate in 2008 from the University of California at Los Angeles followed by postdoctoral training at the University of Toronto. Since 2013, he has been a professor at the Université de Sherbrooke in Québec, Canada and has earned high honors such as Outstanding Canadian New Investigator and National Research Scholar. In addition, his research is federally funded by the Canadian Institutes of Health Research to support his work considered of high scientific caliber that is relevant to a global health need. His laboratory now works in a potential ground-breaking section of antibody-drug conjugate (ADC) research that could propel ADCs into becoming a widespread clinical reality. Specifically, his team researches on technologies that would provide ADCs with better delivery of the chemotherapeutic drugs inside target tumor cells. His approach may change the way we design ADCs in the future.

 
Abstract: The current mechanistic center point ...Read More 

The current mechanistic center point for the success of antibody-drug conjugates (ADCs) is reliant on receptor-mediated endosome entrapment and trafficking to the lysosome where ADC degradation and payload release leads to effective intracellular accumulation and tumor killing. However, cancers cells can respond by shifting endosome trafficking to recycling. This effectively kicks the ADC out of the cell and frustrates delivery. Additionally, cancer cells can increase the expression of drug efflux pumps. When degradation occurs in lysosomes near the cell surface these drugs are quickly and effectively effluxed outside the cell. These two main ADC resistance mechanisms limit high intracellular accumulation of the cytotoxic payload, likely limiting therapeutic efficacy.

The goal of my research program is to design ADCs modified with novel technologies that enable ADCs to escape endosome entrapment and control their own intracellular trafficking in order to deliver cytotoxic payloads with precision and increased intracellular accumulation effectiveness. I will present work from my laboratory that optimizes the design and study of ADCs functionalized with these novel technologies. Results from exploring these advanced ADCs including construction, mechanistic underpinnings and the association with cytotoxicity will be presented and discussed.

Benefits:

  • Advanced intracellular drug-delivery system
  • Increase drug cellular accumulation
  • Increased ADC efficacy
 Read Less
Novel Protein Therapeutics 2017
Emerging Antigens, Neoantigens, and Novel Therapeutic Targets
Moderator: Medha Tomlinson, Abbvie
1:45
Strategies to Address Challenges for Generation of Antigens and Novel Protein Formats
 
Medha Tomlinson
Medha Tomlinson
Principal Research Scientist
Abbvie
About Speaker: Medha Tomlinson received her doctorate in mass spectrometry from the University of Cincinnati and completed her post-doctoral work in protein characterization with Professor Charles Wilkins at the University of California Riverside.  She joined BASF... Read Full Bio 
 
 
Medha Tomlinson
Medha Tomlinson
Principal Research Scientist
Abbvie
 
About Speaker:

Medha Tomlinson received her doctorate in mass spectrometry from the University of Cincinnati and completed her post-doctoral work in protein characterization with Professor Charles Wilkins at the University of California Riverside.  She joined BASF and worked on supporting small molecule projects and her role subsequently expanded to support Biologics programs. She led a group supporting antigen purification and characterization and currently leads the Biologics Protein Purification group at Abbvie within Global Protein Sciences supporting antigen and fusion protein purification for all therapeutic areas.

 
Abstract: Targeting a critical molecule in a pa...Read More 

Targeting a critical molecule in a pathway via a blocking antibody or using an alternative protein or antibody scaffold to signal requires recombinant protein or a cell based immunogen. Various orthologues have to be made to check affinity and species cross reactivity. For challenging targets, construct design is a key aspect of delivering larger quantities of protein reagents. Expression levels have to be adequate to provide enough protein to support many aspects of an early discovery project before a proprietary therapeutic is developed. Often, post translational modifications such as glycosylation play a key role in function. In addition, rapid turnaround of antigen supply is paramount for success.

Here we describe strategies to address expression and purification challenges for protein production and demonstrate successful routes to screen, isolate and enrich for the right antigen. In addition, development towards implementation of a new screening method to predict in vivo half-life of fusion therapeutics will also be shown.

The author is an employee of AbbVie. The design, study conduct, and financial support for this research was provided by AbbVie.  AbbVie participated in the interpretation of data, review, and approval of the publication.

 Read Less
ssclaas=parallelprlval=1Array ( [330] => 1 [329] => 1 [328] => 1 )
2:10
Phenotypic Discovery of Antibody-Target Combinations for Treatment of Cancer
 
Anne Ljungars
Anne Ljungars
Scientist, Preclinical Research
BioInvent International AB
About Speaker: Anne Ljungars has 15+ years of experience in biotech industry and antibody drug development. She currently has a position in the Antibody Discovery team in the Preclinical Research department at BioInvent, Lund, Sweden. As a senior member of this tea... Read Full Bio 
 
 
Anne Ljungars
Anne Ljungars
Scientist, Preclinical Research
BioInvent International AB
 
About Speaker:

Anne Ljungars has 15+ years of experience in biotech industry and antibody drug development. She currently has a position in the Antibody Discovery team in the Preclinical Research department at BioInvent, Lund, Sweden. As a senior member of this team she has coordinated discovery efforts in several antibody drug projects, presently in preclinical or clinical development. She is responsible for high-throughput screening assays and the automated screening platforms at BioInvent and has been a key person in development of the phenotypic antibody-target discovery platform F.I.R.S.T™.

 
Abstract: In the antibody drug development fiel...Read More 

In the antibody drug development field there is a need for new discovery strategies to identify novel targets and first-in-class antibody drugs. We have developed a function-led antibody and target discovery platform (F.I.R.S.T™) including methods for differential cell-based panning (using primary cells and a phage-display library), phenotypic screening and target deconvolution. Two case studies are presented. The first on chronic lymphocytic leukemia, CLL, where the platform has been used to identify antibody-target combinations with superior in vitro and in vivo efficacy compared to standard treatment. Preclinical characterization of a multifunctional antibody (BI-1206) against one of the identified targets, the inhibitory Fcg-receptor CD32b, is described. In the second case study the platform has been applied on regulatory T-cells to generate a panel of Treg targeting antibodies that are currently tested in vivo.

The audience will gain knowledge about:

  • Therapeutic antibody-target combinations for treatment of CLL
  • A multifunctional antibody targeting the inhibitory Fcg-receptor CD32b
  • A function-led approach to identify T-reg specific antibody-target combinations
  • A phenotypic antibody-target discovery platform
 Read Less
2:10
Bioconjugate Techniques for the Efficient and Site-Specific Modification of Single-Chain Proteins and Full-Length Antibodies
 
Andrew Tsourkas
Andrew Tsourkas
Professor, Bioengineering
University of Pennsylvania
About Speaker: Andrew Tsourkas, Ph.D. is a Professor of Bioengineering at the University of Pennsylvania in Philadelphia, PA.  Dr. Tsourkas received his Bachelor’s degree in Mechanical Engineering in 1997 from Cornell University, his Master’s degree in 1999 fr... Read Full Bio 
 
 
Andrew Tsourkas
Andrew Tsourkas
Professor, Bioengineering
University of Pennsylvania
 
About Speaker:

Andrew Tsourkas, Ph.D. is a Professor of Bioengineering at the University of Pennsylvania in Philadelphia, PA.  Dr. Tsourkas received his Bachelor’s degree in Mechanical Engineering in 1997 from Cornell University, his Master’s degree in 1999 from Johns Hopkins University, and his Ph.D. in Biomedical Engineering from the Georgia Institute of Technology/Emory University joint Ph.D. program in 2002.  He then conducted a post-doctoral fellowship in the Department of Radiology at Harvard University, before joining Penn in 2004. Dr. Tsourkas is currently the co-Director for the Center for Targeted Therapeutics and Translational Nanomedicine. He has over 80 peer-reviewed and invited publications and was a recipient of the Wallace H. Coulter Foundation Early Career Award and the National Science Foundation CAREER Award. In 2015, Dr. Tsourkas was also elected as a fellow to the American Institute for Medical and Biological Engineering. Dr. Tsourkas is an inventor on over a dozen patents and has founded four biotechnology companies.

 
Abstract: Many of the standard approaches that ...Read More 

Many of the standard approaches that are used to label antibodies and other targeting ligands with drugs suffer from low reaction efficiencies and non-quantitative, indiscriminate labeling. The value of introducing cargo at specific sites on targeting ligands has become increasingly apparent. However, current site-specific labeling methods can result in low product yields, inefficient drug conjugation, unstable and/or hydrophobic antibody-drug linker chemistry, or incompatibility with glycosylated antibodies. I will discuss several strategies that we have developed that combine chemical and biological bioconjugation techniques to enable the rapid, highly efficient, and site-specific attachment of targeting ligands onto both single chain proteins and full-length antibodies. In this presentation, I will attempt to address the following four questions.

  • What are the limitations of current chemical conjugation techniques?
  • What are the limitations of current biological conjugation techniques?
  • What is the value of site-specifically modifying targeting ligands with cargo?
  • How can chemical and biological conjugation techniques be combined to overcome the shortcomings of each?
 Read Less
2:10
CLEC14a as a Novel Therapeutic Target in Pathological Angiogenesis - A New challenge with antibody-based targeting of VEGF
 
Sukmook Lee
Sukmook Lee
Principal Investigator, Laboratory of Molecular Cancer Therapeutics
Scripps Korea Antibody Institute
About Speaker: Sukmook, Lee is a Principal Investigator of Laboratory of Molecular Cancer Therapeutics in Scripps Korea Antibody Institute (SKAI). He grew up in Korea and received his Ph.D. degree in biochemistry and cellular signaling from the Pohang University of... Read Full Bio 
 
 
Sukmook Lee
Sukmook Lee
Principal Investigator, Laboratory of Molecular Cancer Therapeutics
Scripps Korea Antibody Institute
 
About Speaker:

Sukmook, Lee is a Principal Investigator of Laboratory of Molecular Cancer Therapeutics in Scripps Korea Antibody Institute (SKAI). He grew up in Korea and received his Ph.D. degree in biochemistry and cellular signaling from the Pohang University of Science and Technology (POSTECH) in 2002. Prior to joining SKAI in 2010, he joined National Institute of Health as a postdoctoral associate and Seoul National University as research associate professor for participating in more than six years research experience in the field of antibody engineering. Currently, Sukmook and his team have been focused on developing therapeutic antibodies against novel cancer targets particularly related to tumor angiogenesis and metastasis in collaboration with a wide range of academic and industrial partners.

 
Abstract: Under pathological conditions, high l...Read More 

Under pathological conditions, high levels of VEGF lead to abnormal angiogenesis that is closely associated with the progression and metastasis of various cancers36. Bevacizumab is an anti-angiogenic humanized antibody targeting VEGF that is highly successful and widely used in clinical cancer treatment. However, the clinical usefulness of bevacizumab has been limited by significant side effects and issues with drug resistance. Therefore, the development of additional specific antibody therapeutics is crucial. In this study, we successfully generated a novel anti-angiogenic human monoclonal antibody that targets CLEC14a-CTLD. This is the first study to propose that antibody targeting of CLEC14a-CTLD may be effective to suppress VEGF-dependent and tumor angiogenesis and that the CLEC14a-CTLD may be a novel potential anti-angiogenic target for antibody therapy in pathological angiogenesis.

 Read Less
ssclaas=parallelprlval=1Array ( [330] => 1 [329] => 1 [328] => 1 )
2:35
The Design of Novel Biologics for the Conditional and Unique Engagement of T Cells
 
John Ross
John Ross
Senior Director, Protein Therapeutics
Cue Biopharma
About Speaker: John Ross has been focused on developing protein therapeutics for a number of years (at Genetics Institute (which became Wyeth, and is now Pfizer), Aileron Therapeutics, and Permeon Biologics). He joined Cue Biopharma shortly after its inception in 2... Read Full Bio 
 
 
John Ross
John Ross
Senior Director, Protein Therapeutics
Cue Biopharma
 
About Speaker:

John Ross has been focused on developing protein therapeutics for a number of years (at Genetics Institute (which became Wyeth, and is now Pfizer), Aileron Therapeutics, and Permeon Biologics). He joined Cue Biopharma shortly after its inception in 2015 and is excited to help develop the potentially transformative technology of the company.

 
Abstract: Cue Biopharma is developing novel pro...Read More 

Cue Biopharma is developing novel protein therapeutics designed to target a given T cell population in vivo, create an artificial immune synapse, and thereby modulate that specific T cell population. Each biologic is specifically designed to either trigger activation and proliferation of the target T cell population – generating a robust immune response in oncology – or to induce their depletion and attenuation – reducing pathological immune activity in autoimmune disease. Our biologics are engineered to deliver signaling molecules to T cells with a high level of specificity by fusing the signaling moiety with a peptide-MHC complex. The selective T cell identification molecules (peptides) are interchangeable on the construct, allowing for rapid extension to different indications simply by changing the specific peptide.

 Read Less
2:35
Design and Development of Antibody-Directed Nanotherapeutics (ADNs)
 
Daryl Drummond
Daryl Drummond
Head of Research
Merrimack Pharmaceuticals
About Speaker: Daryl Drummond currently serves as the Head of Research for Merrimack Pharmaceuticals, where he oversees the discovery efforts for Merrimack’s Nanotherapeutics and Biologics-based therapeutics. Dr. Drummond received a Ph.D. degree in Biochemistry f... Read Full Bio 
 
 
Daryl Drummond
Daryl Drummond
Head of Research
Merrimack Pharmaceuticals
 
About Speaker:

Daryl Drummond currently serves as the Head of Research for Merrimack Pharmaceuticals, where he oversees the discovery efforts for Merrimack’s Nanotherapeutics and Biologics-based therapeutics. Dr. Drummond received a Ph.D. degree in Biochemistry from Indiana University in 1997, with an emphasis on membrane biochemistry and biophysics, and later did a postdoc under the renowned father of lipid-based drug delivery systems, Demetrios Papahadjopoulos at UCSF and California Pacific Medical Center. Dr. Drummond was one of two principle inventors for many of Merrimack's nanotechnology-based drugs and platform technologies, most notably Onivyde, a highly stabilized liposomal formulation of irinotecan. He joined Merrimack in October of 2009 following the merger of Merrimack with Hermes Biosciences. Dr. Drummond received a Ph.D. degree in Biochemistry from Indiana University in 1997, with an emphasis on membrane biochemistry and biophysics. He later joined Hermes Biosciences in 2000 as an Associate Director of Liposomal Research and Development following a post-doc in the laboratory of the renowned father of current liposome drug delivery systems, Demetrios Papahadjopoulos. Overall, Dr. Drummond has more than 20 years of experience in the research and development of advanced drug delivery systems, including four unique drugs that have been tested in various clinical trials, >40 issued patents or patent applications, and more than 65 peer reviewed publications focused on lipid-based nanotherapeutics. The focus of his research is in developing targeted nanotherapeutics for treating a wide range of solid tumors. He successfully developed novel platform technologies for targeting lipidic nanocarriers such as liposomes using a range of novel ligands, but most notably Fab’ or scFv antibody fragments. He has also developed platform technologies for dramatically improving the in vivo drug retention of difficult to stabilize small molecule drugs, and for systemic delivery of nucleic acids. Three of their nanotherapeutics are being studied in clinical trials, including an ErbB2-targeted liposomal doxorubicin which is currently being evaluated in a Phase II study in ErbB2-overexpressing breast cancers and a nanoliposomal formulation of irinotecan which recently showed promising results in a Phase III trial in gemcitabine-refractory pancreatic cancer. A fourth antibody targeted lipososomal drug (MM-310) is scheduled to enter the clinic in the second half of 2016.

2:35
MoGRAA® Discovery Engine Can Expand the Drug Targets of Therapeutic mAb
 
Kiyoshi Takayama
Kiyoshi Takayama
Founder, President
NB Health Laboratory
About Speaker: Kiyoshi Takayama has a Ph.D. in pharmaceutical science from the Graduate School of Pharmaceutical Sciences, University of Tokyo, Japan. He worked for more than 12 years as a research scientist at Taisho Pharmaceutical Co., Ltd, Japan, where he was in... Read Full Bio 
 
 
Kiyoshi Takayama
Kiyoshi Takayama
Founder, President
NB Health Laboratory
 
About Speaker:

Kiyoshi Takayama has a Ph.D. in pharmaceutical science from the Graduate School of Pharmaceutical Sciences, University of Tokyo, Japan. He worked for more than 12 years as a research scientist at Taisho Pharmaceutical Co., Ltd, Japan, where he was involved in various drug discovery programs for chronic inflammation and COPD. He also contributed to research on vascular inflammation at Brigham and Women’s Hospital, Harvard Medical School, Boston, USA. After leaving Taisho, Takayama founded NBHL in 2006.

 
Abstract: Currently, In the bio- therapeutic fi...Read More 

Currently, In the bio- therapeutic filed, the targets of therapeutic mAb for inflammation or autoimmune disease, such as cytokine or their receptors, co-stimulatory molecules are getting matured. Other the hand, GPCR is still the attractive targets for various disease area in the field of the small compounds drug discovery, However the success rate of small compounds R&D for GPCR is decreasing now. NBHL proposes “MoGRAA®” (Modification of G-protein coupled Receptor Activation with monoclonal Antibody), a new bio therapeutic concept for GPCR targeted drug discovery for various diseases. NBHL has expertise in functional mAbs targeting multispanning membrane protein such as GPCRs and established MoGRAA® discovery engine. Using this technology, we are discovering promising lead mAbs targeting GPCRs for fibrosis, metabolic diseases, cancer, infection and ocular diseases which are attractive for pharmaceuticals. We would like to show the latest technology of MoGRAA® discovery engine and the property of MoGRAA® mAbs targeting GPCRs for chemokines, peptides and lipid mediators. We propose to run drug discovery programs using these leads mAbs.

 Read Less
ssclaas=parallelprlval=1Array ( [330] => 1 [329] => 1 [328] => 1 )
3:00
Application of the Bispecific DART Platform for Redirected T-cell Killing and Tumor Anchored Immune Co-stimulation
 
Liqin Liu
Liqin Liu
Associate Director, Cell Biology and Immunology
MacroGenics
About Speaker: Liqin Liu is an Associate Director at MacroGenics Inc. She received her PhD from Medical College of Ohio and performed post-doctoral training at Harvard Medical School. Before joining MacroGenics, Liqin worked at Amgen as a Senior Scientist, successf... Read Full Bio 
 
 
Liqin Liu
Liqin Liu
Associate Director, Cell Biology and Immunology
MacroGenics
 
About Speaker:

Liqin Liu is an Associate Director at MacroGenics Inc. She received her PhD from Medical College of Ohio and performed post-doctoral training at Harvard Medical School. Before joining MacroGenics, Liqin worked at Amgen as a Senior Scientist, successfully leading several programs spanning antibody-drug-conjugates, bispecific antibody and small molecule drug discovery and development. During the last four years working at MacroGenics, she has led teams participating in discovery level and middle or late-stage cancer immunotherapy DART (Dual Affinity Re-Targeting) bispecific antibody programs, advancing several programs from preclinical discovery into early clinical development. Liqin has numerous scientific publications on peer reviewed journals and has been involved in several patent filings as a co-inventor.

 
Abstract: Among the most advanced therapeutic s...Read More 

Among the most advanced therapeutic strategies for bispecific based molecules exploits their potential to co-engage T-cells (via CD3 engagement) with a target cell population (via a selectively expressed cell surface antigen) resulting in elimination of the target cell population and concomitant T-cell expansion. Five DART molecules leveraging this mechanism of action for therapeutic targeting various liquid and solid tumors have progressed to clinical evaluation. Data across these programs will be shared illustrating rationale in tumor cell target selection and DART molecular design together with preclinical studies supporting clinical development. Applications extending DART based redirected T-cell killing to infectious diseases and expanding the platform to support immune co-stimulation via tumor cell anchoring will also be shared.

 Read Less
3:00
Treatment of Arthritis by Therapeutic Conjugated to Damaged Cartilage Specific Antibody
 
Ahuva Nissim
Ahuva Nissim
Reader in Antibody and Therapeutic Engineering
Barts and The London, Queen Mary's School of Medicine and Dentistry
About Speaker: Ahuva Nissim graduated in Molecular Immunology in 1992 from the Weizmann Institute of Science in Israel and was trained as a postdoctoral fellow at the MRC Centre for Protein Engineering in Cambridge until 1995. During this period she developed phage... Read Full Bio 
 
 
Ahuva Nissim
Ahuva Nissim
Reader in Antibody and Therapeutic Engineering
Barts and The London, Queen Mary's School of Medicine and Dentistry
 
About Speaker:

Ahuva Nissim graduated in Molecular Immunology in 1992 from the Weizmann Institute of Science in Israel and was trained as a postdoctoral fellow at the MRC Centre for Protein Engineering in Cambridge until 1995. During this period she developed phage display semi-synthetic human antibody library which has been used worldwide. In November 2000 she was appointed as a Senior Lecturer at Queen Mary University. Her studies are interdisciplinary and involve translational research at the William Harvey Research Institute and with intensive worldwide collaborations. Her main research interest focuses on development of targeted immunotherapy, recently highlighted in Nature Review Rheumatology as a basis for development of novel therapy for arthritis (Nature Reviews Rheumatology 10, 511 (2014)  

3:00
The Use of Biosensor Display Libraries in Antibody Discovery and Protein Engineering
 
Michael Gallo
Michael Gallo
President of Research
Innovative Targeting Solutions
About Speaker: Michael Gallo, President of Innovative Targeting Solutions Inc. has been an instrumental contributor to the use and development of transgenic mice for the discovery of human therapeutic antibodies. He was part of the original scientific team at Cell ... Read Full Bio 
 
 
Michael Gallo
Michael Gallo
President of Research
Innovative Targeting Solutions
 
About Speaker:

Michael Gallo, President of Innovative Targeting Solutions Inc. has been an instrumental contributor to the use and development of transgenic mice for the discovery of human therapeutic antibodies. He was part of the original scientific team at Cell Genesys that created XenoMouse, the premier transgenic mouse technology for generating fully human antibodies, and spun-off from Cell Genesys in 1996 to start Abgenix.  As the Vice President of Research at Abgenix Inc. and subsequently Amgen British Columbia, Michael oversaw numerous collaborations including AstraZeneca, Pfizer, Abbot, Curagen, Milleneum, and Dendreon. 

 
Abstract: Advances in antibody drug discovery n...Read More 

Advances in antibody drug discovery now combine de novo antibody sequence diversification with mammalian display. The generation of large fully human antibody repertoires is simply a matter of scaling up a cell line and inducing V(D)J recombination—nature’s most powerful diversity generator—to generate repertoires of greater than one billion unique antibodies. Cell-based biosensors are extremely versatile and can be used to detect a diverse range of biological targets. Detection of binding is highly sensitive due to amplification by signal transduction and reporter gene expression. This talk will describe the coupling of de novo antibody sequence diversification, mammalian display and biosensor technology to generate a powerful new antibody discovery platform we call Biosensor Display. Cell-based biosensor libraries should provide unparalleled access to traditionally challenging targets such as GPCRs, ion channels and multi-subunit complexes in their native environments.

 Read Less
ssclaas=mixsessionprlval=1Array ( [328] => 1 )
3:25
Afternoon Networking Break
ssclaas=mixsessionprlval=1Array ( [328] => 1 )
Novel Protein Therapeutics 2017
General Plenary: Antibody and Protein Discovery Technologies
Moderator: Elad Firnberg, Revolve Biotech
3:55
Precisely Controlled, Highly Diverse Libraries for Drug Discovery and Development
 
Emily Leproust
Emily Leproust
Chief Executive Officer
Twist Bioscience
About Speaker: Emily Leproust, Ph.D. serves as CEO of Twist Bioscience. Dr. Leproust is disrupting the process of gene synthesis to enable exponential growth of synthetic biology applications. She was named one of Foreign Policy’s 100 Leading Global Thinkers and ... Read Full Bio 
 
 
Emily Leproust
Emily Leproust
Chief Executive Officer
Twist Bioscience
 
About Speaker:

Emily Leproust, Ph.D. serves as CEO of Twist Bioscience. Dr. Leproust is disrupting the process of gene synthesis to enable exponential growth of synthetic biology applications. She was named one of Foreign Policy’s 100 Leading Global Thinkers and one of the most creative people in business by Fast Company.

ssclaas=mixsessionprlval=1Array ( [328] => 1 )
4:20
Expansive Mutagenesis for Affinity Binder Discovery
 
Elad Firnberg
Elad Firnberg
CEO
Revolve Biotech
About Speaker: Dr. Firnberg is CEO and co-founder of Revolve Biotechnologies, a biotech company specializing in DNA library construction for antibody and protein engineering. Dr. Firnberg received his Ph.D. in Chemical and Biomolecular Engineering at Johns Hopkins ... Read Full Bio 
 
 
Elad Firnberg
Elad Firnberg
CEO
Revolve Biotech
 
About Speaker:

Dr. Firnberg is CEO and co-founder of Revolve Biotechnologies, a biotech company specializing in DNA library construction for antibody and protein engineering. Dr. Firnberg received his Ph.D. in Chemical and Biomolecular Engineering at Johns Hopkins University, where his research focused on understanding protein evolution through mapping enzyme mutational fitness landscapes. At Revolve he has launched the company's library generation service using its patented PFunkel mutagenesis technology. 

 
Abstract: Efficient access to comprehensive mut...Read More 

Efficient access to comprehensive mutation sequence space remains challenging and expensive using traditional methods. Revolve has developed PFunkel mutagenesis technology for building expansive DNA mutation libraries useful for advanced protein engineering. We demonstrate rapid construction of amino acid scanning and multi-site libraries. We have developed high-throughput oligo design software based on Tm optimization using mismatch nearest-neighbor hybridization thermodynamics. We use next-generation sequencing of libraries to demonstrate balanced mutational distribution, wildtype content <0.4%, and library sizes >10^11. This talk will discuss application of our library approach for rapid in vitro discovery of ultra-affinity scFv binders. We demonstrate generation of highly diverse scFv CDR libraries with up to 21 contiguous degenerate codons. We use in vitro display combined with a novel flow-based off-rate selection system. By taking advantage of our ability to rapidly access and screen expansive sequence space, we can perform serial rounds of affinity maturation in short time frames and reach highly specific ultra-affinity binding.

 Read Less
ssclaas=mixsessionprlval=1Array ( [328] => 1 )
4:45
Application of Vaccinia Display to Complex Membrane Antigens
 
Ernest Smith
Ernest Smith
Senior Vice President, Research & CSO
Vaccinex
About Speaker: I joined Vaccinex at its inception in 1997 and was a key developer of its core cDNA library and antibody discovery technologies. In my current position, I am responsible for and contributes to the company’s research and technology development proje... Read Full Bio 
 
 
Ernest Smith
Ernest Smith
Senior Vice President, Research & CSO
Vaccinex
 
About Speaker:

I joined Vaccinex at its inception in 1997 and was a key developer of its core cDNA library and antibody discovery technologies. In my current position, I am responsible for and contributes to the company’s research and technology development projects, and am a member of the clinical development team. I have a Ph.D. in Microbiology and Immunology from the University of Rochester.

 
Abstract: We have developed an antibody discove...Read More 

We have developed an antibody discovery platform that enables efficient mammalian cell based expression of a library of human antibodies in full length IgG format on the surface of both a mammalian virus and the cell surface. This allows us to combine the advantages of virus panning and cell sorting into one seamless selection process. This technology enables the rapid selection of >1010 antibody combinations and thus selection of high affinity leads with varied frameworks that recognize multiple epitopes. The selected antibodies are ideally suited for development because they have already passed mammalian cell quality control during the selection process.

We have also modified this fusion protein technology to enable the direct incorporation of multipass membrane proteins such as GPCRs into the viral membrane. This method is rapid, does not require any detergents or refolding, and can be applied to multiple different mammalian cell types in order to maximize protein expression. Antigen expressing virus can be readily purified and used for antibody selection.

 Read Less
ssclaas=mixsessionprlval=1Array ( [328] => 1 )
5:10
Characterization of Monoclonal Antibodies (mAb) Using PEAKS AB Software Platform
 
Lin He
Lin He
Principal Application Scientist
Bioinformatics Solutions Inc
About Speaker: Dr. Lin He is the Principal Application Scientist of Bioinformatics Solutions Inc. (BSI), which is one of the leading suppliers of mass spectrometry data analysis software and service. He graduated from University of Waterloo, Canada, as a Ph.D. in B... Read Full Bio 
 
 
Lin He
Lin He
Principal Application Scientist
Bioinformatics Solutions Inc
 
About Speaker:

Dr. Lin He is the Principal Application Scientist of Bioinformatics Solutions Inc. (BSI), which is one of the leading suppliers of mass spectrometry data analysis software and service. He graduated from University of Waterloo, Canada, as a Ph.D. in Bioinformatics and then joined the Yates Lab at The Scripps Research Institute as a Research Associate. He joined in BSI in 2015, mainly contributing to the protein de novo sequencing service and software development for antibody protein characterization.

 
Abstract: Studies of therapeutic proteins, espe...Read More 

Studies of therapeutic proteins, especially monoclonal antibodies (mAbs), require complete and accurate protein sequences and comprehensive characterization of chemical environment of each amino acid, for example, post-translational modification (PTM), glycosylation, sequence variants, and disulfide linkages. It has been proven that current LC-MS technologies can provide an accurate and sensitive solution for both mAb sequencing and characterization. However, it is difficult to transfer LC-MS/MS data to mAb knowledges for researchers without a powerful software tool. We propose such a software platform, PEAKS AB, which can be easily used to carry out mAb protein de novo sequencing and analyses of PTMs, sequence variants, and disulfide linked peptides.

 Read Less
ssclaas=mixsessionprlval=1Array ( [328] => 1 )
5:35
Novel MicroScale Solutions for Biophysical Characterization of Biological Therapeutics
 
Wyatt Strutz
Wyatt Strutz
Senior Application Specialist
NanoTemper Technologies
About Speaker: Wyatt Strutz received a dual B.Sc & M.Sc in Biomedical Engineering from Drexel University, located in Philadelphia, PA. Before joining NanoTemper Technologies in 2012, he was developing cartilage scaffolds dually between Drexel University and Uni... Read Full Bio 
 
 
Wyatt Strutz
Wyatt Strutz
Senior Application Specialist
NanoTemper Technologies
 
About Speaker:

Wyatt Strutz received a dual B.Sc & M.Sc in Biomedical Engineering from Drexel University, located in Philadelphia, PA. Before joining NanoTemper Technologies in 2012, he was developing cartilage scaffolds dually between Drexel University and University of Pennsylvania School of Medicine. He also has experience developing enzymatic and cell-based assays for global pharmaceutical companies. Currently, Wyatt leads a team in the rapidly expanding North American biophysical market.

 
Abstract: Here we present two unique technologi...Read More 

Here we present two unique technologies for biophysical characterization of biomolecules and their applications for biological therapeutics:

The Monolith, utilizing MicroScale Thermophoresis (MST), monitors the movement of molecules through µm-sized temperature gradients to quantify interactions of any kind of biomolecule, including large molecules. The method is buffer independent, allowing one to quickly quantify interactions in simple buffers, or more complex conditions, such as plasma or other crude contexts. In addition, Monolith systems automatically detect secondary effects such as protein aggregation and denaturation, reliably distinguishing false positives. We describe a case study quantify Fab and Fc interactions of a mAb, using one assay protocol.

The Prometheus, utilizing nanoDSF & Backreflection technology, measures thermal and chemical unfolding/refolding and aggregation. By monitoring fluorescence shifts of tryptophan and tyrosine residues, unfolding profiles of multidomain proteins, transmembrane proteins or low-abundant drug targets can be obtained in a label-free format. In addition, Backreflection optics simultaneously characterize aggregation formation and propensity. We describe case studies of mAb formulation, long-term stability analysis, biosimiliar profiling, and ADC linking evaluation using the Prometheus system.

 Read Less
ssclaas=mixsessionprlval=1Array ( [328] => 1 )
6:00
Evening Networking Reception
ssclaas=mixsessionprlval=1Array ( [328] => 1 )
7:00
End of Day 1
ssclaas=mixsessionprlval=1Array ( [328] => 1 )
Day 2 - Wednesday, July 12, 2017
 
7:15
Breakfast with Mentors from Academia & Industry
ssclaas=mixsessionprlval=1Array ( [328] => 1 )
Novel Protein Therapeutics 2017
General Plenary: Advances in Antibody Engineering
Moderator: Ahuva Nissim, Barts and The London, Queen Mary's School of Medicine and Dentistry
8:30
HuMab Chickens: The Next Generation Antibody Discovery Platform
 
Bill Harriman
Bill Harriman
CSO, Co-Founder
Crystal Bioscience
About Speaker: Bill Harriman, Ph.D., is a co-founder and Chief Scientific Officer of Crystal Bioscience, which was founded in 2008 with the mission to create a platform for antibody discovery featuring wild-type and engineered birds. His prior experience at biotech... Read Full Bio 
 
 
Bill Harriman
Bill Harriman
CSO, Co-Founder
Crystal Bioscience
 
About Speaker:

Bill Harriman, Ph.D., is a co-founder and Chief Scientific Officer of Crystal Bioscience, which was founded in 2008 with the mission to create a platform for antibody discovery featuring wild-type and engineered birds. His prior experience at biotech and pharma companies including Trellis Bioscience, Roche, and Abgenix involved roles as project manager, antibody group leader, and technology developer.

 
Abstract: Transgenic rodents producing human se...Read More 

Transgenic rodents producing human sequence antibodies are widely accepted as a reliable source of therapeutic candidates. However, their repertoires are limited by their evolutionary similarity to humans. Crystal Bioscience has expanded the repertoire of transgenic animals by engineering HuMab chickens producing fully human sequence, high affinity mAbs. In addition to revealing novel epitopes and, therefore novel IP, the Crystal Platform yields mAbs recognizing murine orthologs of human antigens that facilitate pre-clinical studies.

 Read Less
ssclaas=mixsessionprlval=1Array ( [328] => 1 )
8:55
Antibody-Display Libraries in Mammalian Cells Created Using CRISPR/Cas9 and TALE Nucleases
 
Peter Slavny
Peter Slavny
Project Leader and Co-Founder
IONTAS
About Speaker: Peter received a PhD in biochemistry from the John Innes Centre in Norwich, UK. He subsequently joined the McCafferty laboratory at the University of Cambridge, UK, as a post-doctoral researcher working on therapeutic antibody discovery by phage disp... Read Full Bio 
 
 
Peter Slavny
Peter Slavny
Project Leader and Co-Founder
IONTAS
 
About Speaker:

Peter received a PhD in biochemistry from the John Innes Centre in Norwich, UK. He subsequently joined the McCafferty laboratory at the University of Cambridge, UK, as a post-doctoral researcher working on therapeutic antibody discovery by phage display. He was a co-founder of IONTAS ltd in 2012, where he is currently a Project Leader running antibody discovery campaigns to diverse and challenging target classes. 

 
Abstract: Using directed integration of antibod...Read More 

Using directed integration of antibody genes by CRISPR/Cas9 and TALE nucleases we have constructed large libraries in mammalian cells containing a single antibody gene/cell. This has permitted construction of populations of millions of monoclonal stable cell lines displaying antibodies on their surface from which novel binders including IgG formatted antibodies, have been isolated using flow cytometry or antigen coated magnetic beads.

 Read Less
ssclaas=mixsessionprlval=1Array ( [328] => 1 )
9:20
Transgenic Human IgG Platforms and NGS-based Bioinformatics for Fast and Effective Discovery & Engineering of Multispecific Therapeutics
 
Omid  Vafa
Omid Vafa
Chief Business Officer
TENEObio
About Speaker: Omid Vafa is the Chief Business Officer at Teneobio, Inc. He has more that 15 years of global business and scientific experience in biotechnology and pharmaceutical drug discovery, asset evaluation, transactions and licensing. Prior to joining TeneoB... Read Full Bio 
 
 
Omid  Vafa
Omid Vafa
Chief Business Officer
TENEObio
 
About Speaker:

Omid Vafa is the Chief Business Officer at Teneobio, Inc. He has more that 15 years of global business and scientific experience in biotechnology and pharmaceutical drug discovery, asset evaluation, transactions and licensing. Prior to joining TeneoBio, Omid was the Director of Strategy and Scientific Partnerships at Janssen Pharmaceutical Companies of Johnson and Johnson and the Biotechnology and Oncology Lead at the London Innovation Center of J&J. Omid earned his doctorate at Georgetown University, his MBA from the Villanova University School of Business, and his B.S. from the University of California at Irvine. He completed his post-doctoral fellowships at The Scripps Research Institute (TSRI) and the Salk Institute for Biological Studies in La Jolla, California. 

 
Abstract: Transgen...Read More 

Transgenic rodents have enabled the discovery of human antibodies against targets of therapeutic interest.  Next generation sequencing and bioinformatics has further powered the identification of diverse immunoglobulin leads from the B cell repertoire of such immunized rodents. Here, we describe a proprietary discovery platform TeneoSeek™, that has enabled us to identify and engineer bi- and multispecific therapeutic antibodies from UniRat™ (expressing heavy chain only UniAbs™) and OmniFlic® (expressing fixed light chain antibodies) transgenic platforms.  This session will provide an overview of the application of these technologies towards the engineering of differentiated and tailored multispecific therapeutics for desirable biological functions, including tune-able T cell activation and targeted cancer cell killing. 

 Read Less
ssclaas=mixsessionprlval=1Array ( [328] => 1 )
9:45
Targeted Fc Gamma Receptor Mediated Clearance of Soluble Antigen by a Biparatopic Bispecific Antibody
 
Srinath Kasturirangan
Srinath Kasturirangan
Scientist, Antibody Discovery and Protein Engineering
MedImmune
About Speaker: I have been working as a Scientist I at Medimmune since November 2010. My primary responsibilities are generation and characterization of novel bispecific antibodies, antibody engineering for stability and half life improvements and technology develo... Read Full Bio 
 
 
Srinath Kasturirangan
Srinath Kasturirangan
Scientist, Antibody Discovery and Protein Engineering
MedImmune
 
About Speaker:

I have been working as a Scientist I at Medimmune since November 2010. My primary responsibilities are generation and characterization of novel bispecific antibodies, antibody engineering for stability and half life improvements and technology development. Prior to working at Medimmune, I got my PhD in Bioengineering at Arizona State Univerisity, working on Antibody based therapeutics for Alzheimer's disease in the lab of Dr Mike Sierks. At ASU, we developed a novel biopanning technique combining the imaging capability of atomic force microscopy with phage display to isolate scFv against low concentrations of specific brain derived oligomers of beta amyloid. I have also worked on catalytic antibodies that can cleave beta amyloid at specific sites. I have several publications in peer reviewed journals and patents.

 
Abstract: Monoclonal antibodies targeting solub...Read More 

Monoclonal antibodies targeting soluble factors can significantly increase the half-life of their ligands by FcRn-mediated antibody recycling, requiring increasingly high antibody doses to neutralize the increasing pool of target. Here we present an approach to rapidly clear soluble antigen using a biparatopic bispecific antibody that can form large complexes with its target antigen and target it to the liver for clearance by an Fcgamma Receptor mediated mechanism.

Benefits of presentation:

  1. Novel bispecific antibody design and application
  2. Novel mechanism of soluble antigen clearance
  3. Topic of interest to broad audience in protein / antibody engineering fields
  4. Represents next wave of biologics
 Read Less
ssclaas=mixsessionprlval=1Array ( [328] => 1 )
10:10
Tailoring Bi- or Multi-Specific Formats for Different Therapeutic Modalities
 
Syd Johnson
Syd Johnson
Vice President, Antibody Engineering
Macrogenics
About Speaker: ... Read Full Bio 
 
 
Syd Johnson
Syd Johnson
Vice President, Antibody Engineering
Macrogenics
 
About Speaker:
 
Abstract: We continue to discover  novel a...Read More 

We continue to discover  novel and optimal ways to utilize bispecific DART® and trivalent TRIDENT™ formats for clinical use. This talk will focus on how factors such as relative positioning, affinitiy and the valency of the binding domains are optimized for specific therapeutic indications. Examples will highlight the advantages of several formats  of DART and TRIDENT proteins that take advantage of the power and flexibility of platform.

 Read Less
ssclaas=mixsessionprlval=1Array ( [328] => 1 )
10:35
Morning Networking Break
ssclaas=parallelprlval=0Array ( [328] => 5 )
Round Table Discussions

Array ( [3428] => Array ( [sheduleid] => 3428 [new_session] => 1 [single_conf] => 0 [cfid] => 328 [schedule_type] => speakerslot [prev] => 1499855700 [next] => 1499861100 ) [3429] => Array ( [sheduleid] => 3429 [new_session] => 0 [single_conf] => 0 [cfid] => 328 [schedule_type] => speakerslot [prev] => 1499855700 [next] => 1499861100 ) [4476] => Array ( [sheduleid] => 4476 [new_session] => 0 [single_conf] => 0 [cfid] => 328 [schedule_type] => speakerslot [prev] => 1499855700 [next] => 1499861100 ) [4478] => Array ( [sheduleid] => 4478 [new_session] => 0 [single_conf] => 0 [cfid] => 328 [schedule_type] => speakerslot [prev] => 1499855700 [next] => 1499861100 ) [4477] => Array ( [sheduleid] => 4477 [new_session] => 0 [single_conf] => 0 [cfid] => 328 [schedule_type] => speakerslot [prev] => 1499855700 [next] => 1499861100 ) )
11:05
ssclaas=mixsessionprlval=1Array ( [328] => 1 )
12:05
Lunch Provided by GTCbio
ssclaas=parallelprlval=0Array ( [328] => 4 )
Plenary Panel: Regulatory Considerations of Bringing Antibody Therapies to Market
Moderator: Owen Fields, Pfizer
Array ( [3416] => Array ( [sheduleid] => 3416 [new_session] => 1 [single_conf] => 0 [cfid] => 328 [schedule_type] => speakerslot [prev] => 1499861100 [next] => 1499869200 ) [3417] => Array ( [sheduleid] => 3417 [new_session] => 0 [single_conf] => 0 [cfid] => 328 [schedule_type] => speakerslot [prev] => 1499861100 [next] => 1499869200 ) [3418] => Array ( [sheduleid] => 3418 [new_session] => 0 [single_conf] => 0 [cfid] => 328 [schedule_type] => speakerslot [prev] => 1499861100 [next] => 1499869200 ) [3657] => Array ( [sheduleid] => 3657 [new_session] => 0 [single_conf] => 0 [cfid] => 328 [schedule_type] => speakerslot [prev] => 1499861100 [next] => 1499869200 ) )
1:20
Owen Fields
Owen Fields
Vice President Regulatory Strategy
Pfizer
 
Owen Fields
Owen Fields
Vice President Regulatory Strategy
Pfizer
 
About Speaker:

Owen joined Pfizer with the merger of Pfizer and Wyeth. Owen joined Wyeth in 1995, and was responsible for providing regulatory strategy advice for many of Wyeth’s biological products. Prior to Wyeth, Owen served as a review team leader at the United States Food and Drug Administration, where he helped develop and shape US regulatory policy towards food biotechnology. Owen has a BS in Biochemistry and a minor in mathematics from Wichita State University and received his Ph.D. from the Department of Molecular and Cellular Biology at the University of California, Berkeley in 1991.

Dan Zhang
Dan Zhang
Chairman and CEO
Fountain Medical Development
 
Dan Zhang
Dan Zhang
Chairman and CEO
Fountain Medical Development
 
About Speaker:

Dr. Dan Zhang is the Chairman and CEO of Fountain Medical Development Ltd, a full-service clinical CRO with 1300 employees operating in China, Hong Kong, Taiwan, South Korea, Japan, UK, India, Philippines, Armenia and USA.

Dr. Zhang was the Head of Clinical Development at Sigma-Tau Research Inc, He was a vice president at the Quintiles Transnational Corp. and the Chairman of the Board, Quintiles Medical Development (Shanghai) Company Ltd.,

Dr. Zhang is a member of grant application review committee for National Key Drug Development Fund of China, and is also a consultant for the China Food and Drug Administration (CFDA). He is chairing the committee of Pharmaceutical R&D, China Pharmaceutical Industry Research and Development Association. He was a member of the Overseas Expert Committee on New Drug R&D for the Ministry of Science and Technology of China, and was the secretary-general of the Association of “Thousand Talent” Expert

Dr. Zhang received his pre-med training from Peking University and received his M.D. from Peking Union Medical College. He then went to the Harvard School of Public Health and received an MPH in health policy and management. Then he went to the Wharton Business School of the University of Pennsylvania, where he obtained his master’s degree in healthcare management in 1998.

Ezio Bonvini
Ezio Bonvini
Senior Vice President of Research
Macrogenics
 
Ezio Bonvini
Ezio Bonvini
Senior Vice President of Research
Macrogenics
 
About Speaker:

Dr. Bonvini, Senior Vice President, Research and Chief Scientific Officer, joined Macrogenics in June 2003. From 1985 to 2003, Dr. Bonvini was with the FDA in the Center for Biologics Evaluation and Research, or CBER, which is responsible for regulating therapeutic monoclonal antibodies and other proteins, ultimately serving as Acting Deputy Director, Division of Monoclonal Antibodies and Chief, Laboratory of Immunobiology. From 1982 to 1984, Dr. Bonvini was a Visiting Fellow at the National Cancer Institute at the National Institutes of Health. Dr. Bonvini received a Diploma in Science from the Scientific Lyceum in Genoa, Italy, and his M.D. and Specialty Certification in Clinical Hematology from the University of Genoa, School of Medicine.

Amy Grenham
Amy Grenham
Director, Regulatory Affairs
MedImmune
 
Amy Grenham
Amy Grenham
Director, Regulatory Affairs
MedImmune
 
About Speaker:

Amy Grenham serves as a Global Regulatory Lead at MedImmune/AstraZeneca responsible for regulatory strategy development to support all phases of drug development. She has more than 15 years’ experience in the biotechnology field with a focus on development of protein therapeutics including vaccines for infectious diseases. Amy has a BS in Biology from the University of Connecticut and MS from the University of Michigan Department of Molecular and Cellular Biology and has earned Regulatory Affairs Certification (US, Europe).

ssclaas=mixsessionprlval=1Array ( [328] => 1 )
Novel Protein Therapeutics 2017
Keynote Plenary Session – The Future of Antibody & Protein Therapeutics
Moderator: Victor-Jeffrey Leyton, Université de Sherbrooke
2:20
Engineering Antibodies for Functionality and Safety: Atoms-Up Approach
 
John Williams
John Charles Williams
Professor, Department of Molecular Medicine
City of Hope
About Speaker: John is professor of molecular medicine at the Beckman Research Institute of the City of Hope, where he also serves as a member of the Developmental Cancer Therapeutics Program as well as Co-Director of the Drug Discovery and Structural Biology Core.... Read Full Bio 
 
 
John Williams
John Charles Williams
Professor, Department of Molecular Medicine
City of Hope
 
About Speaker:

John is professor of molecular medicine at the Beckman Research Institute of the City of Hope, where he also serves as a member of the Developmental Cancer Therapeutics Program as well as Co-Director of the Drug Discovery and Structural Biology Core.

The main focus of John’s research centers on the application of structural and biophysical methods to understand the biological role of multivalency and energy additivity on multicomponent, macromolecular complexes and how to manipulate these properties to develop novel, highly specific agonists and antagonists. His lab also discovered the meditope binding site while investigating alternative methods of modulating properties of protein therapeutics.

John earned his B.S. in chemistry from the University of California at Santa Cruz and his Ph.D. in chemistry from Columbia University. He was an Alexander von Humboldt postdoctoral fellow at the European Molecular Biology Laboratories in Heidelberg, Germany and an HHMI and Leukemia and Lymphoma Society Special Fellow at Columbia-Presbyterian Medical Center.

ssclaas=mixsessionprlval=1Array ( [328] => 1 )
3:05
End of Summit